Why Is Biomanufacturing So Hard?

Technology Review
July 15, 2011

Earlier this year, the Cambridge-based biotech firm Genzyme announced the latest in a series of manufacturing delays for Fabrazyme, a biological drug that treats a rare genetic disorder, after one lot of the drug was found to be contaminated. The news followed a more severe setback in 2009, when both Fabrazyme and another drug were contaminated with a virus; the problem closed the manufacturing plant and created major shortages.

Genzyme isn't alone in these issues. Biologics—drugs made through a biological process rather than chemical synthesis, a category that includes recombinant proteins, vaccines, and antibodies—are the fastest-growing segment of the pharmaceutical industry. In 2008, nearly 30 percent of revenue from the top 100 drugs came from biologics, a figure that is expected to rise to 50 percent by 2014.

But the same factors that make biologics powerful drugs also make them a challenge to manufacture. They typically mimic proteins and other molecules found in living organisms and can target harmful entities, such as some cancer cells, with great accuracy; many of the most promising new drugs for cancer and other diseases fall into this class. Biologics tend to be larger, more complex molecules than drugs synthesized through chemical reactions, which adds to production challenges and makes them costly. A single dose of some biologic therapies can cost $10,000.
To read more click here...